ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
DealStreetAsia

Singapore Hummingbird to start COVID antibody therapy trial

SK-backed startup receives approval from local authorities

 A nurse cares for a COVID-19 patient in the intensive care unit at King Chulalongkorn Memorial Hospital in Bangkok on April 23, 2020.   © Reuters

SINGAPORE -- Cancer antibody developer Hummingbird Bioscience has received approval from Singapore health authorities to start a clinical trial for COVID-19 antibody therapy.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more